Resources

Publications

07/13/2022
- Oncology
Integration of Tumor Extrinsic and Intrinsic Features Associates With Immunotherapy Response in Non-small Cell Lung Cancer
Nature Communications, Tempus-authored
07/02/2022
- Oncology
Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC)
ESMO World Congress on Gastrointestinal Cancer 2022
06/28/2022
- Oncology
Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
Cancers
06/16/2022
- Oncology
Comprehensive Genomic Profiling in Advanced/Metastatic Colorectal Cancer: Number Needed to Test and Budget Impact of Expanded First Line Use
Journal of Medical Economics, Tempus-authored
06/14/2022
- Oncology
Pilot Study: PARP1 Imaging in Advanced Prostate Cancer
Molecular Imaging and Biology
06/08/2022
- Oncology
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
JCO Precision Oncology, Tempus-authored
06/06/2022
- Oncology
Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer
JCO Precision Oncology, Tempus-authored
05/28/2022
- Oncology
Validation of Genomic and Transcriptomic Models of Homologous Recombination Deficiency in a Real-world Pan-Cancer Cohort
BMC Cancer, Tempus-authored
05/26/2022
- Oncology
Circulating Tumor DNA (ctDNA) Mutations Associate With Response in Patients (Pts) With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Treated With Talazoparib (TALA) and Temozolomide (TMZ)
ASCO 2022
05/26/2022
- Oncology
Microsatellite-Stable Tumors With High Tumor Mutational Burden in Association With Tumor Response to Immune Checkpoint Inhibitor Therapy Across Solid Tumors and Correlation With Specific Oncogenic Alterations
ASCO 2022

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31